Results 271 to 280 of about 329,623 (303)

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

Lancet, The, 2022
Ayan Dey
exaly  

Immunogenicity.

Annals of Internal Medicine, 1973
openaire   +2 more sources

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Lancet, The, 2020
Maheshi N Ramasamy, Angela M Minassian, Pedro M Folegatti   +2 more
exaly  

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Cell, 2020
Daniel K Wells, Kristen K Dang, Kathleen Sheehan   +2 more
exaly  

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Lancet, The, 2021
Alasdair P S Munro, Victoria R Cornelius, Parvinder Aley   +2 more
exaly  

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet, The, 2020
Feng-Cai Zhu, Tao Jiang, Jun Zhang
exaly  

Immunogenic

2011
openaire   +2 more sources

Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial

Lancet, The, 2023
Mathieu Mateo
exaly  

Immunogenicity

Immunopharmacology, 1988
openaire   +1 more source

The determinants of tumour immunogenicity

Nature Reviews Cancer, 2012
Thomas Blankenstein, Elizabeth M Jaffee, Eli Gilboa   +2 more
exaly